3 days ago · Basel, 12 February 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved a New Drug Application …

We are partnering with people living with spinal muscular atrophy (SMA) and patient organisations to explore multiple approaches to treatment that help improve lives. SMA is an autosomal …

4 hours ago · Basel: Roche, announced that the U.S. Food and Drug Administration (FDA) has approved a New Drug Application (NDA) for an Evrysdi (risdiplam) tablet for people living with …

2 days ago · Roche is investigating more than a dozen medicines for neurological disorders, including multiple sclerosis, spinal muscular atrophy, neuromyelitis optica spectrum disorder, …

2 days ago · Genentech and Roche are investigating more than a dozen medicines for neurological disorders, including multiple sclerosis, spinal muscular atrophy, neuromyelitis …

1 day ago · The approval, granted to Roche subsidiary Genentech, makes Evrysdi the only noninvasive disease-modifying therapy for spinal muscular atrophy (SMA), according to the …

Evrysdi, marketed by Genentech, a Roche company, is a disease-modifying therapy designed to target the genetic root cause of SMA by increasing the production of the missing functional …

Evrysdi is an approved treatment for spinal muscular atrophy (SMA) in adults, children and infants from birth. Evrysdi is a survival motor neuron-2 (SMN2) mRNA splicing modifier designed to …

Spinal muscular atrophy, normally called ‘SMA’, describes a genetic disorder with different degrees of severity associated with the loss of motor neurons and disease-related …

1 day ago · The FDA has approved Roche’s Evrysdi (risdiplam) tablet, making it the first and only treatment for spinal muscular atrophy (SMA) available in the tablet form. According to the …